Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d] imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Manik, Aleksandra
  • Diez Iriepa, Daniel|||0000-0002-8575-1246
  • Szałaj , Natalia
  • Marco Contelles, José Luis
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Martínez Alonso, Borja
  • Guarnizo Herrero, Víctor|||0000-0001-9323-3388
  • Torrado Durán, Guillermo|||0000-0002-8865-2083
As part of a project aimed at the pharmacological optimization of Contilisant, herein we describe molecular modelling studies that led to the identification of MBA-159 as a new polyfunctionalized, multitarget-directed ligand and a promising drug candidate for the treatment of Alzheimer?s disease. We synthesized MBA-159 and conducted comprehensive in vitro and in vivo evaluations. In in vivo studies MBA-159 demonstrated favourable pharmacokinetics, anti-amnesic properties and significantly improved non-spatial memory (contextual and recognition memory) in a mouse model of scopolamine-induced amnesia. Additionally, MBA-159 showed a tendency to increase synaptic plasticity biomarkers and reduce neuroinflammatory trends (assessed by qPCR), as well as cognitive enhancement in a senescence-accelerated prone mouse 8 model., Ministerio de Ciencia e Innovación, Ministerio de Economía, Comercio y Empresa